Latest News

A drug for heart conditions improves efficacy of melanoma therapies

A collaborative study undertaken by the Navarrabiomed Biomedical Research Center (Pamplona, ??Navarre), the Institute of Neurosciences CSIC-UMH (Sant Joan d’Alacant, Valencian Community) and IRB Barcelona (Barcelona, ??Catalonia) shows that the administration of ranolazine, a drug currently used to treat heart conditions, improves the efficacy of current therapies for melanoma, in mouse models of this disease.

Read More
MRV News
Melanoma News
Archive
Menu